GILD Earnings

Gilead Sciences Announces Second Quarter 2025 Financial Results

Published August 07, 2025 at 08:02 PM

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #Earnings--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for Gilead, including the FDA approval for Yeztugo as the world’s first twice-yearly HIV prevention option,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio. As we enter

Related Questions

What is the potential impact on Gilead’s cash flow and R&D budget from the new product launch? What guidance is Gilead providing for Q3 earnings and revenue growth? What are the projected sales contributions of Biktarvy, Descovy, Trodelvy, and Livdelzi for Q3 and FY2025? How does the market expect the new twice‑yearly HIV prevention option to affect Gilead’s market share versus competitors like ViiV and Pfizer? Will the diversification of Gileod’s portfolio reduce reliance on any single product’s sales? How does the Q2 performance compare to analyst consensus estimates and prior guidance? How will Yeztugo’s FDA approval impact Gilead’s revenue guidance for the rest of 2025? What are the expected adoption rates and pricing strategy for Yeztugo in the U.S. and international markets? What are the key risks (regulatory, reimbursement, competitive) that could offset the positive impact of the new approval? Will the earnings beat translate into immediate price movement and increased buying pressure on GILD?